Strength training linked to less lean-tissue loss in weight-loss trial

• Resistance-training group: 22.28 kilograms lost on average.
• Non-training group: 22.61 kilograms lost on average.
• Lean tissue: About 25% less lost by the resistance-training group.
• Strength: Upper- and lower-body strength rose by around 10% in the training group and fell by about 10% in the non-training group.

Those nearly identical weight-loss averages make the muscle and strength findings more useful. People can shed a similar amount of weight and still have a different physical result, depending on whether the program protects strength alongside the scale weight.

Why does preserving muscle matter?

Weight loss often removes some lean tissue as well as fat. Lean tissue includes muscle, bones, organs and water, so a lower weight does not automatically mean that muscle has been preserved.

Strong muscles help people climb stairs, carry shopping, rise from chairs and remain active as they age. Weight loss that leaves someone weaker may not deliver all the hoped-for benefits, including greater independence and continued activity.

For people taking weight-loss medicines such as tirzepatide or semaglutide, resistance exercise may therefore do more than support general fitness. It may help preserve the physical function that successful weight management should support.

What can resistance training add?

Resistance training can include lifting weights, using exercise machines or performing appropriately challenging body-weight movements. The best program depends on a person's age, fitness, health conditions and previous experience.

People who are new to strength training may benefit from professional guidance.

The practical takeaway is simple: weight-loss medication and strength training can work together rather than compete.

What does the trial leave unanswered?

The trial was relatively small and lasted 40 weeks. It cannot establish whether the strength gains will persist for years or whether resistance training will reduce future disability.

It also studied one age group and one medication. The sample included men and postmenopausal women aged 50 to 70, all taking tirzepatide, so results may differ in other populations or with semaglutide.

The findings therefore do not settle how people with type 2 diabetes, adults outside the studied age range or users of other weight-loss drugs will respond. Those groups were outside this trial's design.

Even with those limits, the results support a broader goal for weight management: reduce excess body fat while protecting physical function. Pursuing the lowest possible scale weight may be less useful if treatment leaves a person weaker.

For now, the clearest lesson is to judge weight-loss treatment by strength and everyday function as well as kilograms lost.